Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven mainly by volume growth from key drugs like Mounjaro and Zepbound, with earnings per share beating estimates. Despite a bullish pipeline and raised revenue guidance, the company faces challenges including declining drug prices, significant acquisition-related charges, and competition from generics abroad. The stock trades at a premium valuation that depends on successful drug approvals and stable pricing, leading analysts to recommend holding shares until clearer pricing trends and regulatory outcomes emerge in Q3.
As of Sep 15, 2026 20:21 WIB, Eli Lilly (LLY) shares are trading at USD 1,157.00 on Pluang, showing a 1.69% increase in the last day. The company holds a market capitalization of $1.01 trillion and offers a dividend yield of 0.61%. These figures highlight the premium valuation Eli Lilly currently enjoys despite the challenges noted by analysts.
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and is expanding its incretin franchise with promising new drugs like retatrutide and Foundeo. In contrast, Merck's Q2 revenue grew only 5%, with...
The Harbor Health Care ETF returned 15.30% in the second quarter of 2026, led by strong gains in biotechnology stocks fueled by clinical data and merger activity. Pharmaceutical stocks lagged due to the ETF's lower exposure to Eli Lilly, a major benc...
Eli Lilly's stock fell 8.44% in the past month despite strong business growth, driven by concerns over pricing and acquisition charges. The company leads the obesity and diabetes market with blockbuster drugs Mounjaro and Zepbound, generating $14.9 b...
August's inflation report showed headline inflation steady and core inflation falling to its lowest in over five years, signaling easing price pressures. Despite this positive data, the Federal Reserve is still expected to raise interest rates to con...
The iShares U.S. Pharmaceuticals ETF (IHE) provides focused exposure to the US pharmaceutical sector, heavily weighted towards Johnson & Johnson and Eli Lilly. It benefits from growth drivers like obesity therapies and strong drug pipelines but carri...
